Modality
Fusion Protein
MOA
BCMA ADC
Target
PLK4
Pathway
Ferroptosis
PSPMelanoma
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
~Oct 2018
→ ~Jan 2020
Phase 2
Apr 2020
→ Oct 2029
Phase 2Current
NCT08802784
464 pts·Melanoma
2021-09→TBD·Not yet recruiting
NCT04429917
2,743 pts·PSP
2020-04→2029-10·Terminated
3,207 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-193mo agoPDUFA· Melanoma
2029-10-183.6y awayPh3 Readout· PSP
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Termina…
P2/3
Not yet…
Catalysts
PDUFA
2025-12-19 · 3mo ago
Melanoma
Ph3 Readout
2029-10-18 · 3.6y away
PSP
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08802784 | Phase 2/3 | Melanoma | Not yet recr... | 464 | VA |
| NCT04429917 | Phase 2/3 | PSP | Terminated | 2743 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |